ADIAL PHARMACEUTICALS, INC. 8K

Adial Pharmaceuticals announced completion of its Azora Therapeutics acquisition, a concurrent $32 million private placement tranche, a large non‑cash IPR&D charge driving a $52 million quarterly net loss, and a strategic pivot to inflammatory disease with plans to advance AT177 for ulcerative colitis into the clinic by 2027.

On August 17, 2026, Adial Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting the completion of its acquisition of Azora Therapeutics, which adds lead ulcerative colitis candidate AT177 and shifts the company’s strategic focus to serious inflammatory diseases, and the closing of the initial $32 million tranche (including $5.5 million of note conversions) of an up to $64 million private placement led by biotech-focused investors; the company disclosed a significant non‑cash $46.2 million acquired in‑process R&D charge related to the Azora transaction, higher G&A expenses driven by merger and severance costs, a resulting $52.0 million quarterly net loss and a stockholders’ deficit driven by a milestone warrant liability and mezzanine equity classification of Series A convertible preferred stock, while stating that its $28.7 million in cash and equivalents is expected to fund operations into the second half of 2027 and outlining plans to file an IND for AT177 in the first half of 2027 and commence Phase 1 clinical trials in the second half of 2027.

Filing Facts

CIK

1513525

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-090482

Alert Tier

7